Fundraising FoxBolden
Providence, US · 3 known investors
Find your way into Bolden
Sign up to see every warm intro you have to Bolden
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bolden team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bolden Therapeutics is a biotechnology company developing therapeutics that promote neurogenesis—the formation of new brain cells—to treat neurological and central nervous system diseases such as Alzheimer's. Its lead approach uses exon-skipping antisense oligonucleotides, with multiple therapeutic modalities in preclinical development.
Also known as Bolden Therapeutics, Inc.
Founders & leadership
Investors · 3
Company profile
researched Aug 2026Bolden Therapeutics is a biotechnology company founded in 2019 and based at 225 Dyer Street, Floor 2, Providence, Rhode Island. It is developing first-in-class therapeutics for central nervous system diseases, with stated indications including Alzheimer's disease and ischemic stroke.
The company's approach targets a molecular pathway that stimulates neurogenesis — the generation of new neurons — in the adult brain. According to Brown University's Nelson Center for Entrepreneurship, this pathway has demonstrated proof of concept in mouse models, indicating the program was at a preclinical stage as of that account.
Founding story
Bolden Therapeutics was founded in 2019 by Johnny Page (Brown class of '24), Justin Fallon, a Professor of Neuroscience, and Ashley Webb, an Assistant Professor of Molecular and Cell Biology, with ties to Brown University. John (Johnny) Page is listed as Co-Founder and CEO and Justin R. Fallon, Ph.D., as CSO and Co-Founder.
Traction
Progress reported includes proof of concept for its neurogenesis pathway in mouse models, selection as a 2021 Brown Venture Prize finalist, and a $500,000 Phase I STTR grant from the National Institute on Aging in 2021.
Latest developments
The most recent development recorded is the 2021 receipt of a $500,000 Phase I STTR grant from the National Institute on Aging and its status as a 2021 Brown Venture Prize finalist.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Bolden Therapeutics describes its therapeutics as first-in-class within central nervous system disease treatment, positioning itself around adult neurogenesis as a therapeutic mechanism.
Technology
The company's technology centers on a key molecular pathway that stimulates neurogenesis, the birth of new neurons, in the adult brain. Proof of concept for the pathway has been demonstrated in mouse models.
Go-to-market
The stated disease targets are central nervous system conditions, including Alzheimer's disease and ischemic stroke.
Geography
Headquartered in Providence, Rhode Island, United States, with founding ties to Brown University.
History
The company was established in 2019. In 2021 it was named a finalist for the Brown Venture Prize and is listed as a Brown Venture Prize alum. That same year it received a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThe company was a finalist for the Brown Venture Prize in 2021 and is listed as a Brown Venture Prize alum by Brown University's Nelson Center for Entrepreneurship.
Bolden Therapeutics received a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging.
$500K source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Bolden Therapeutics | Nelson Center for Entrepreneurship | Brown Universityentrepreneurship.brown.edu · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Bolden do?
- Providence-based biotech developing first-in-class therapeutics that stimulate adult neurogenesis for CNS diseases.
- Who founded Bolden?
- Bolden was founded by Johnny Page, Ashley Webb, Justin Fallon.
- Who are Bolden's investors?
- Bolden's investors include Slater Technology Fund, Lifespan Vision Ventures, Partners Resolute.
- Where is Bolden headquartered?
- Bolden is headquartered in Providence, US.